Literature DB >> 17429847

Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals.

Aihua Song1, Jianxun Song, Xiaohong Tang, Michael Croft.   

Abstract

The relative contribution of OX40 (CD134) to priming of CD8 T cells in complex systems where CD4 and CD8 cells respond and cooperate together is not clear. We previously found that OX40 expressed on tumor-reactive CD8 T cells controls their initial persistence when adoptively transferred in vivo and is required for delayed tumor growth. We now show that exogenous stimulation of OX40 with agonist antibody augments its ability to suppress the growth of new as well as established tumors, correlating with marked expansion of adoptively transferred CD8 T cells. Concomitantly, anti-OX40 strongly enhanced the number of tumor antigen-reactive CD4 T cells. Moreover, the augmented accumulation of CD8 T cells was prevented in animals lacking MHC class II or depleted of CD4 cells and did not occur in OX40-deficient animals receiving wild-type CD8 cells, demonstrating that non-CD8 cells are the major target of OX40 signals. These results suggest that while OX40 signaling to a CD8 T cell can control its expansion, OX40 expressed on non-CD8 cells strongly influences CD8 priming and in vivo activity. OX40 therefore represents an important signal for allowing effective cooperation between CD4 and CD8 cells and for promoting cell interplay and tumor rejection where CD8 activity is limiting.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429847     DOI: 10.1002/eji.200636957

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

Review 1.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

2.  Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.

Authors:  Stefanie N Linch; Melissa J Kasiewicz; Michael J McNamara; Ian F Hilgart-Martiszus; Mohammad Farhad; William L Redmond
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

Review 3.  Control of immunity by the TNFR-related molecule OX40 (CD134).

Authors:  Michael Croft
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 4.  The significance of OX40 and OX40L to T-cell biology and immune disease.

Authors:  Michael Croft; Takanori So; Wei Duan; Pejman Soroosh
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival.

Authors:  Jianxun Song; Takanori So; Michael Croft
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

6.  OX40 signaling directly triggers the antitumor effects of NKT cells.

Authors:  Dapeng Zhou
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

7.  Eradication of spontaneous malignancy by local immunotherapy.

Authors:  Idit Sagiv-Barfi; Debra K Czerwinski; Shoshana Levy; Israt S Alam; Aaron T Mayer; Sanjiv S Gambhir; Ronald Levy
Journal:  Sci Transl Med       Date:  2018-01-31       Impact factor: 17.956

Review 8.  Integrating costimulatory agonists to optimize immune-based cancer therapies.

Authors:  Angela D Pardee; Amy K Wesa; Walter J Storkus
Journal:  Immunotherapy       Date:  2009-03       Impact factor: 4.196

9.  OX40 agonist combined with irreversible electroporation synergistically eradicates established tumors and drives systemic antitumor immune response in a syngeneic pancreatic cancer model.

Authors:  Qi-Wei Zhang; Xiao-Xia Guo; Yu Zhou; Qing-Bing Wang; Qin Liu; Zhi-Yuan Wu; Xiao-Yi Ding
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

10.  OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

Authors:  Daniel Hirschhorn-Cymerman; Gabrielle A Rizzuto; Taha Merghoub; Adam D Cohen; Francesca Avogadri; Alexander M Lesokhin; Andrew D Weinberg; Jedd D Wolchok; Alan N Houghton
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.